Nektar Therapeutics (NKTR) stock
Close on Nov 12, 2026Market cap $1.27BP/E –Yield –
Nektar Therapeutics saw revenue fall 43.9% to $55.23M over the twelve months to Dec 31, 2025. Free cash flow was -$208.68M. At the latest close the market valued the company at $1.27B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.27B
- P/E ratio
- –
- Price to sales
- 23.03
- Price to book
- 1.50
- Dividend yield
- –
- Free cash flow yield
- -16.41%
Fundamentals
- Revenue
- $55.23M
- Net income
- -$164.08M
- EPS, diluted
- -$9.73
- Free cash flow
- -$208.68M
- Book value per share
- $24.86
- Diluted shares
- 34M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $38.44
- Open
- $38.32
- Day's range
- $37.01 – $38.32
- Volume
- 775,137
- Average volume (20 days)
- 647,392
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 2.05
- 52-week range
- $33.40 – $109.00
- RSI (14 days)
- 37.8
- Volatility (1 year)
- 84.1%
- Relative volume
- 0.79×
- WACC
- 15.3%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NKTR | S&P 500 | Difference | NKTR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.5% | -2.7% | −3.8 pts | ||
| 3 months | -51.0% | -1.7% | −49.3 pts | ||
| Year to date | -11.9% | +11.9% | −23.8 pts | ||
| 1 year | -35.4% | +12.0% | −47.4 pts | ||
| 3 years | +451.9% | +78.2% | +373.7 pts | +76.7% | +21.2% |
| 5 years | -81.4% | +73.2% | −154.6 pts | -28.6% | +11.6% |
| 10 years | -82.8% | +309.6% | −392.4 pts | -16.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nektar Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- News
About Nektar Therapeutics
Pharmaceutical Preparations
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical enterprise focused on discovering and developing medicines in the field of immunotherapy. The company develops immunomodulatory agents engineered to selectively induce, amplify, attenuate, or prevent immune responses. Its pipeline focuses on treatments for autoimmune conditions and oncology, featuring therapeutic candidates such as rezpegaldesleukin and NKTR-0165/NKTR-0166 for autoimmune diseases, alongside NKTR-255 for cancer indications. Nektar primarily engages with global biopharmaceutical companies and partners through licensing, collaboration, and supply agreements.
Company profile, executives and historyNektar Therapeutics stock: common questions
What is Nektar Therapeutics's stock price?
NKTR closed at $37.25 on Nov 12, 2026, down 3.10% on the day. Over the past 52 weeks it traded between $33.40 and $109.00.
What is Nektar Therapeutics's market cap?
Nektar Therapeutics was worth $1.27B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NKTR's P/E ratio?
Nektar Therapeutics lost money over the twelve months to Dec 31, 2025 (diluted EPS -$9.73), so it has no meaningful P/E ratio.
How much revenue does Nektar Therapeutics make?
Nektar Therapeutics reported revenue of $55.23M for the twelve months to Dec 31, 2025, down 43.9% from a year earlier.
Does Nektar Therapeutics pay a dividend?
No. Nektar Therapeutics has not paid a cash dividend over the last twelve months.
When does Nektar Therapeutics report earnings next?
Nektar Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has NKTR stock performed over the past year?
Including dividends, NKTR returned -35.4% over the past year, against +12.0% for the S&P 500.
How many NKTR shares are sold short?
7M shares were sold short at the latest FINRA report, 19.91% of the float, or 10.3 days of average trading volume.
Who are Nektar Therapeutics's competitors?
Companies most similar to Nektar Therapeutics by business, industry and size include XLO, CUE, QTTB, TNGX, EQ.
See a number that looks wrong?